Unilife Mention in Biodel's 4th Qtr Results

Today, after the close, Biodel announced 4th Qtr Results. Dr. Errol De Souza, president and chief executive officer mentioned Unilife in the following statement:

"We continue to advance the GEM program with the initiation of the Phase 1 proof of concept study which will allow us to select the appropriate comparator for pivotal trials while our partner, Unilife, manufactures the molds necessary for production and delivery to Biodel of registration lots. We look forward to reporting top line data from Study 3-151 early next month and reporting top line results of the Phase 1 proof-of-concept GEM study and the initiation of the Phase 2b BIOD-531 study in the first half of 2015."